Charles Knight
University of Toledo Medical Center
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Charles Knight.
Nature Biotechnology | 2006
Roger Canales; Yuling Luo; James C. Willey; Bradley Austermiller; Catalin Barbacioru; Cecilie Boysen; Kathryn Hunkapiller; Roderick V. Jensen; Charles Knight; Kathleen Y Lee; Yunqing Ma; Botoul Maqsodi; Adam Papallo; Elizabeth Herness Peters; Karen Poulter; Patricia L. Ruppel; Raymond R. Samaha; Leming Shi; Wen Yang; Lu Zhang; Federico Goodsaid
We have evaluated the performance characteristics of three quantitative gene expression technologies and correlated their expression measurements to those of five commercial microarray platforms, based on the MicroArray Quality Control (MAQC) data set. The limit of detection, assay range, precision, accuracy and fold-change correlations were assessed for 997 TaqMan Gene Expression Assays, 205 Standardized RT (Sta)RT-PCR assays and 244 QuantiGene assays. TaqMan is a registered trademark of Roche Molecular Systems, Inc. We observed high correlation between quantitative gene expression values and microarray platform results and found few discordant measurements among all platforms. The main cause of variability was differences in probe sequence and thus target location. A second source of variability was the limited and variable sensitivity of the different microarray platforms for detecting weakly expressed genes, which affected interplatform and intersite reproducibility of differentially expressed genes. From this analysis, we conclude that the MAQC microarray data set has been validated by alternative quantitative gene expression platforms thus supporting the use of microarray platforms for the quantitative characterization of gene expression.
Methods of Molecular Biology | 2004
James C. Willey; Erin L. Crawford; Charles Knight; Kristy A. Warner; Cheryl A. Motten; Elizabeth A. Herness; Robert Zahorchak; Timothy G. Graves
Standardized reverse transcriptase polymerase chain reaction (StaRT-PCR) is a modification of the competitive template (CT) RT method described by Gilliland et al. StaRT-PCR allows rapid, reproducible, standardized, quantitative measurement of data for many genes simultaneously. An internal standard CT is prepared for each gene, cloned to generate enough for 10(9) assays and CTs for up to 1,000 genes are mixed together. Each target gene is normalized to a reference gene to control for cDNA loaded in a standardized mixture of internal standards (SMIS) into the reaction. Each target gene and reference gene is measured relative to its respective internal standard within the SMIS. Because each target gene and reference gene is simultaneously measured relative to a known number of internal standard molecules in the SMIS, it is possible to report each gene expression measurement as a numerical value in units of target gene cDNA molecules/ 10(6) reference gene cDNA molecules. Calculation of data in this format allows for entry into a common databank, direct interexperimental comparison, and combination of values into interactive gene expression indices.
The Journal of Molecular Diagnostics | 2003
Kristy A. Warner; Erin L. Crawford; Aiman Zaher; Robert J. Coombs; Haitham Elsamaloty; Stacie L. Roshong-Denk; Imran Sharief; Guillermo V. Amurao; Yongsook Yoon; Amro Y. Al-Astal; Ragheb Assaly; Dawn-Alita R. Hernandez; Timothy G. Graves; Charles Knight; Michael W. Harr; Todd Sheridan; Jeffrey P. DeMuth; Robert Zahorchak; Jeffrey R. Hammersley; Dan E. Olson; Samuel J. Durham; James C. Willey
Morphological analysis of cytologic samples obtained by fine-needle aspirate (FNA) or bronchoscopy is an important method for diagnosing bronchogenic carcinoma. However, this approach has only about 65 to 80% diagnostic sensitivity. Based on previous studies, the c-myc x E2F-1/p21WAF1/CIP1 (p21 hereafter) gene expression index is highly sensitive and specific for distinguishing normal from malignant bronchial epithelial tissues. In an effort to improve sensitivity of diagnosing lung cancer in cytologic specimens, we used Standardized Reverse Transcriptase Polymerase Chain Reaction (StaRT-PCR) to measure the c-myc x E2F-1/p21 index in cDNA samples from 14 normal lung samples (6 normal lung parenchyma and 8 normal bronchial epithelial cell [NBEC] biopsies), and 16 FNA biopsies from 14 suspected tumors. Based on cytomorphologic criteria, 11 of the 14 suspected tumors were diagnosed as bronchogenic carcinoma and three specimens were non-diagnostic. Subsequent biopsy samples confirmed that the three non-diagnostic samples were derived from lung carcinomas. The index value for each bronchogenic carcinoma was above a cut-off value of 7000 and the index value of all but one normal sample was below 7000. Thus the c-myc x E2F-1/p21 index may augment cytomorphologic diagnosis of bronchogenic carcinoma biopsy samples, particularly those considered non-diagnostic by cytomorphologic criteria.
Archive | 2006
James C. Willey; Brad Austermiller; Erin L. Crawford; Charles Knight; Terry Osborn; Robert Zahorchak
Archive | 2006
James C. Willey; Brad Austermiller; Erin L. Crawford; Charles Knight; Terry Osborn; Robert Zahorchak
Archive | 2006
James C. Willey; Brad Austermiller; Erin L. Crawford; Charles Knight; Terry Osborn; Robert Zahorchak
Archive | 2006
James C. Willey; Brad Austermiller; Erin L. Crawford; Charles Knight; Terry Osborn; Robert Zahorchak
Clinical Chemistry | 2007
Elizabeth Herness Peters; Sandra Rojas-Caro; Mitchell G. Brigell; Robert Zahorchak; Shelley Ann des Etages; Patricia L. Ruppel; Charles Knight; Bradley Austermiller; Myrna C. Graham; Steve Wowk; Sean Banks; Lakshmi V. Madabusi; Patrick Turk; Donna Wilder; Carole Kempfer; Terry Osborn; James C. Willey
Chest | 2004
James C. Willey; Charles Knight; Erin L. Crawford; Dan E. Olson; Jeffrey Hammersly; Youngsook Yoon; Imran Sharief
Archive | 2006
James C. Willey; Brad Austermiller; Erin L. Crawford; Charles Knight; Terry Osborn; Robert Zahorchak